National Heart and Lung Institute, Heart Science Centre, Harefield Hospital, London, UK.
Institute of Biomedical Engineering, Imperial College London, London, UK.
Nat Rev Cardiol. 2018 Dec;15(12):770-779. doi: 10.1038/s41569-018-0103-z.
The epidemics of heart failure and, to a lesser extent, of pulmonary arterial hypertension continue unabated worldwide and are extremely costly in terms of loss of life and earnings, as well as the burden of health-care expenditure due to repeated hospitalization. The effectiveness of newly discovered therapies for the two conditions depends on their timely application. To date, symptoms have been used to guide the application and timing of therapy. Compelling evidence now exists that symptoms are preceded by several metabolic and haemodynamic changes, particularly a rise in intravascular pressures during exercise. These observations have stimulated the development of several implantable devices for the detection of impending unstable heart failure or pulmonary arterial hypertension, necessitating admission to hospital. In this Review, we summarize the rationale for monitoring patients with heart failure or pulmonary arterial hypertension, the transition from noninvasive to implantable devices and the current and anticipated clinical uses of these devices.
心力衰竭的流行,以及在较小程度上的肺动脉高压的流行,在全球范围内仍在持续,并且在生命损失和收入方面以及由于反复住院而导致的医疗保健支出负担方面代价极高。两种疾病的新发现疗法的有效性取决于其及时应用。迄今为止,症状一直被用于指导治疗的应用和时机。现在有令人信服的证据表明,症状之前会出现一些代谢和血液动力学的变化,特别是在运动期间血管内压力升高。这些观察结果激发了几种用于检测即将发生的不稳定心力衰竭或肺动脉高压的植入式设备的开发,这些设备需要住院治疗。在这篇综述中,我们总结了监测心力衰竭或肺动脉高压患者的基本原理,从非植入式设备到植入式设备的转变,以及这些设备目前和预期的临床用途。